39.40
price down icon3.08%   -1.25
after-market Handel nachbörslich: 38.50 -0.90 -2.28%
loading
Schlusskurs vom Vortag:
$40.65
Offen:
$40.39
24-Stunden-Volumen:
369.52K
Relative Volume:
0.80
Marktkapitalisierung:
$2.55B
Einnahmen:
$87.56M
Nettoeinkommen (Verlust:
$-167.47M
KGV:
-16.84
EPS:
-2.34
Netto-Cashflow:
$-148.20M
1W Leistung:
-10.72%
1M Leistung:
-1.77%
6M Leistung:
-9.72%
1J Leistung:
+20.90%
1-Tages-Spanne:
Value
$38.96
$40.48
1-Wochen-Bereich:
Value
$38.96
$45.31
52-Wochen-Spanne:
Value
$29.24
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
Firmenname
Kymera Therapeutics Inc
Name
Telefon
857-285-5314
Name
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
Mitarbeiter
184
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
KYMR's Discussions on Twitter

Vergleichen Sie KYMR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KYMR
Kymera Therapeutics Inc
39.40 2.55B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.52 113.70B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.27 75.52B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
654.76 39.78B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.99 35.34B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
121.16 29.05B 3.30B -501.07M 1.03B -2.1146

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-10 Eingeleitet BTIG Research Buy
2024-12-06 Eingeleitet BMO Capital Markets Market Perform
2024-12-02 Hochstufung Wells Fargo Equal Weight → Overweight
2024-11-18 Eingeleitet Stephens Overweight
2024-09-09 Fortgesetzt Leerink Partners Outperform
2024-08-26 Hochstufung Wolfe Research Peer Perform → Outperform
2024-04-22 Eingeleitet Oppenheimer Outperform
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2024-01-04 Hochstufung JP Morgan Neutral → Overweight
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-12-19 Herabstufung Wells Fargo Overweight → Equal Weight
2023-06-30 Eingeleitet Truist Buy
2023-05-05 Hochstufung Raymond James Mkt Perform → Outperform
2022-12-06 Herabstufung Credit Suisse Outperform → Neutral
2022-11-08 Eingeleitet Raymond James Mkt Perform
2022-08-15 Eingeleitet Jefferies Buy
2022-08-03 Eingeleitet Goldman Buy
2022-07-20 Eingeleitet SVB Leerink Mkt Perform
2022-04-28 Eingeleitet Credit Suisse Outperform
2022-03-10 Eingeleitet JP Morgan Neutral
2022-02-10 Eingeleitet Wells Fargo Overweight
2021-09-30 Eingeleitet B. Riley Securities Neutral
2021-09-30 Eingeleitet Stifel Buy
2021-09-10 Herabstufung BofA Securities Buy → Neutral
2021-05-21 Eingeleitet UBS Buy
2021-04-14 Eingeleitet Berenberg Buy
2020-12-04 Eingeleitet H.C. Wainwright Buy
2020-09-15 Eingeleitet BofA Securities Neutral
2020-09-15 Eingeleitet Cowen Outperform
2020-09-15 Eingeleitet Guggenheim Buy
2020-09-15 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten

pulisher
Jan 26, 2025

(KYMR) Technical Data - Stock Traders Daily

Jan 26, 2025
pulisher
Jan 26, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Average PT from Brokerages - Defense World

Jan 26, 2025
pulisher
Jan 23, 2025

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $55.06 - MarketBeat

Jan 23, 2025
pulisher
Jan 21, 2025

Kymera Therapeutics (NASDAQ:KYMR) Earns "Overweight" Rating from Stephens - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Kymera announces expansion of KT-474 HS and AD phase 2 studies - MSN

Jan 21, 2025
pulisher
Jan 17, 2025

Kymera Therapeutics soars as Sanofi expands phase 2 trials - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.3%Time to Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Kymera Therapeutics (NASDAQ:KYMR) Provides Business Update and Preliminary Cash Balance for 2024 - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Kymera Therapeutics describes IRAK-4 degraders - BioWorld Online

Jan 16, 2025
pulisher
Jan 16, 2025

How the (KYMR) price action is used to our Advantage - Stock Traders Daily

Jan 16, 2025
pulisher
Jan 16, 2025

JPMorgan Chase & Co. Acquires 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Jan 16, 2025
pulisher
Jan 16, 2025

JPMorgan Chase & Co. Purchases 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

Kymera Provides Pipeline Objectives for 2025, Stock Gains - MSN

Jan 15, 2025
pulisher
Jan 14, 2025

Kymera rises after presentation at the J.P. Morgan event - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutio - GuruFocus.com

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera stock surges on product pipeline update By Investing.com - Investing.com Canada

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments - Yahoo Finance

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics (NASDAQ:KYMR) Trading 6.4% HigherHere's Why - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera reports progress in immunology drug trials By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics Shares Surge Amid 2025 Strategy Unveil - TipRanks

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera reports progress in immunology drug trials - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - The Manila Times

Jan 14, 2025
pulisher
Jan 14, 2025

Kymera Unveils Ambitious 2025 Immunology Pipeline Plans with $850M Cash Runway - StockTitan

Jan 14, 2025
pulisher
Jan 09, 2025

Analysts Set Expectations for KYMR FY2029 Earnings - Defense World

Jan 09, 2025
pulisher
Jan 08, 2025

Stifel sustains Buy on Kymera stock amid TPD drug optimism By Investing.com - Investing.com UK

Jan 08, 2025
pulisher
Jan 08, 2025

Equities Analysts Set Expectations for KYMR FY2029 Earnings - MarketBeat

Jan 08, 2025
pulisher
Jan 07, 2025

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 - The Manila Times

Jan 07, 2025
pulisher
Jan 07, 2025

Kymera Therapeutics to Present Strategic Roadmap at J.P. Morgan Healthcare Conference - StockTitan

Jan 07, 2025
pulisher
Jan 06, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock - MarketBeat

Jan 06, 2025
pulisher
Jan 05, 2025

(KYMR) Trading Report - Stock Traders Daily

Jan 05, 2025
pulisher
Jan 02, 2025

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online

Jan 02, 2025
pulisher
Jan 01, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $53.88 Consensus Price Target from Brokerages - Defense World

Jan 01, 2025
pulisher
Dec 29, 2024

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $53.88 - MarketBeat

Dec 29, 2024
pulisher
Dec 29, 2024

Vir Biotechnology (NASDAQ:VIR) & Kymera Therapeutics (NASDAQ:KYMR) Financial Contrast - Defense World

Dec 29, 2024
pulisher
Dec 28, 2024

Kymera Therapeutics (NASDAQ:KYMR) Receives “Outperform” Rating from Leerink Partners - Defense World

Dec 28, 2024
pulisher
Dec 27, 2024

Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal - Yahoo Finance

Dec 27, 2024
pulisher
Dec 27, 2024

Leerink Partners Reaffirms Outperform Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat

Dec 27, 2024
pulisher
Dec 26, 2024

Trading (KYMR) With Integrated Risk Controls - Stock Traders Daily

Dec 26, 2024
pulisher
Dec 24, 2024

Geode Capital Management LLC Sells 996 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Dec 24, 2024
pulisher
Dec 21, 2024

HighTower Advisors LLC Takes $494,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

BMO Capital Initiates Coverage of Kymera Therapeutics (KYMR) with Market Perform Recommendation - MSN

Dec 20, 2024
pulisher
Dec 17, 2024

BTIG Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - MSN

Dec 17, 2024
pulisher
Dec 17, 2024

State Street Corp Has $81.79 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Verition Fund Management LLC - Defense World

Dec 16, 2024
pulisher
Dec 15, 2024

(KYMR) Investment Analysis - Stock Traders Daily

Dec 15, 2024
pulisher
Dec 10, 2024

Kymera Therapeutics (NASDAQ:KYMR) Now Covered by BTIG Research - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

Two Sigma Advisers LP Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Wellington Management Group LLP Has $218.59 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at BMO Capital Markets - Defense World

Dec 09, 2024
pulisher
Dec 07, 2024

Kymera: Protein Degradation Could Drive Dupixent-Like Value (NASDAQ:KYMR) - Seeking Alpha

Dec 07, 2024

Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Kymera Therapeutics Inc-Aktie (KYMR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Jacobs Bruce N.
Chief Financial Officer
Jan 10 '25
Option Exercise
2.08
10,000
20,800
178,921
Chiniara Ellen
Chief Legal Officer
Jan 06 '25
Sale
41.75
3,129
130,645
54,826
$40.72
price down icon 9.39%
$21.64
price down icon 7.91%
$372.75
price up icon 0.51%
$5.21
price up icon 6.11%
biotechnology ONC
$226.71
price up icon 0.02%
$121.16
price down icon 2.53%
Kapitalisierung:     |  Volumen (24h):